Zinc therapy for night blindness in cystic fibrosis
نویسندگان
چکیده
منابع مشابه
Night Blindness and Diabetes in a Non-Caucasian Cystic Fibrosis Patient in Iran
Cystic fibrosis (CF) is an autosomal recessive lethal disease that is predominantly occur in the caucasian populations and causes many clinical signs. The major clinical signs are pancreatic insufficiency and progressive lung disease but night blindness and diabetes are less well known. We report a fifteen years old non-caucasian girl that have cystic fibrosis with atypical night blindness, dia...
متن کاملNight blindness and conjunctival xerosis caused by vitamin A deficiency in patients with cystic fibrosis.
Forty three patients with cystic fibrosis, aged 8-44 years (median 16 years), were examined for evidence of vitamin A deficiency. Eight patients had abnormal dark adaptation tests and three had conjunctival xerosis. Serum vitamin A and retinol binding protein concentrations were significantly lower in the affected patients who were also more likely to have abnormal liver function tests. Five pa...
متن کاملBarriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in CFTR genes that affect chloride ion channel. The CF is a good nominee for gene therapy as the asymptomatic carriers are phenotypically normal, and the desired cells are accessible for vector delivery. Gene therapy shows promising effects involving the correction of gene or replacement of the mutant gene with the func...
متن کاملGene therapy for cystic fibrosis.
Following the cloning of the cystic fibrosis (CF) gene, in vitro studies rapidly established the feasibility of gene therapy for this disease. Unlike ex vivo approaches that have been utilized for other genetic diseases such as adenosine deaminase deficiency, gene therapy for CF will likely require direct in vivo delivery of gene transfer vectors to the airways of patients with CF. Hence, major...
متن کاملGene therapy in cystic fibrosis.
Theoretically, cystic fibrosis transmembrane conductance regulator (CFTR) gene replacement during the neonatal period can decrease morbidity and mortality from cystic fibrosis (CF). In vivo gene transfers have been accomplished in CF patients. Choice of vector, mode of delivery to airways, translocation of genetic information, and sufficient expression level of the normalized CFTR gene are issu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cystic Fibrosis
سال: 2008
ISSN: 1569-1993
DOI: 10.1016/j.jcf.2007.11.005